You are here

  • Home
  • Archive
  • Volume 4, Issue Suppl 1
  • 462 Antimalarials improve survival of systemic lupus erythematosus on cholesterol: results of a fifteen-year chinese multicenter retrospective study in jiangsu province

Article Text

Article menu

Download PDFPDF

Poster Session
SLE Epidemiology and risk factors
462 Antimalarials improve survival of systemic lupus erythematosus on cholesterol: results of a fifteen-year chinese multicenter retrospective study in jiangsu province
Free
  1. F Wang1,
  2. W Zhang1,
  3. S Wang1,
  4. W Pan2,
  5. L Liu3,
  6. M Wu4,
  7. X Ding5,
  8. H Wei6,
  9. Y Zou7,
  10. X Feng1 and
  11. L Sun1
  1. 1Affiliated Drum Tower Hospital of Medical School – Nanjing University, Department of Rheumatology and Immunology, Nanjing, China
  2. 2Huaian First People’s Hospital, Department of Rheumatology-, Huaian, China
  3. 3Xuzhou Central Hospital, Department of Rheumatology, Xuzhou, China
  4. 4Third Affiliated Hospital of Soochow University, Department of Rheumatology, Changzhou, China
  5. 5Lianyungang First People’s Hospital, Department of Rheumatology, Lianyungang, China
  6. 6Subei People’s Hospital of Jiangsu province, Department of Rheumatology, Yangzhou, China
  7. 7Wuxi People’s Hospital, Department of Rheumatology, Wuxi, China

Abstract

Background and aims Nowadays the importance of antimalarials, especially hydroxychloroquine (HCQ) and chloroquine (CQ), in treatment of systemic lupus erythematosus (SLE) has been demonstrated. However, few have examined the efficacy of HCQ and CQ on eastern Chinese SLE patients.

Methods The analysis is based on 1372 patients who were enrolled in a retrospective study of 26 centres from January 1st, 1999 through December 31st, 2009, during which time is their first hospitalisation. Baseline and follow-up clinical, laboratory and therapeutic data and survival status before April 30th, 2015 were recorded. Statistical analysis consist of Chi-square test, t-test, Kaplan-Meier curves and logrank test.

Results Compared with 562 patients without HCQ or CQ treatment, the hazard ratio (HR) of deaths in 810 patients taking those was reduced (HR 0.52, 95% CI 0.38–0.70, p<0.001). 376 of these 1372 patients experienced their second hospitalisation, during which treating group (165 of 376) showed high blood level of total cholesterol (TG), compared to control group (4.47 (0.13) vs 5.03 (0.21), p=0.027), while no statistical difference of TG exists between the two groups’ first hospitalisation (p>0.05). Other metabolic data, such as systolic and diastolic blood pressure, fasting blood sugar, triglyceride and uric acid were similar between the two groups in two times of hospitalisation. On second inpatient visit, disease activity (SLE disease activity index, blood sedimentation rate, complement) and organ involvements of antimalarials takers and no users showed no significant differences either.

Abstract 462 Figure 1
Abstract 462 Figure 1

Conclusions Use of HCQ or CQ lower the risk of mortality and TG levels of eastern Chinese SLE patients.

https://doi.org/10.1136/lupus-2017-000215.462

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.